Modulation of the Immune Response by Deferasirox in Myelodysplastic Syndrome Patients

• Главные авторы: Hana Votavova (Автор), Zuzana Urbanova (Автор), David Kundrat (Автор), Michaela Dostalova Merkerova (Автор), Martin Vostry (Автор), Monika Hruba (Автор), Jaroslav Cermak (Автор), Monika Belickova (Автор)
• Формат: ‌
• Опубликовано: MDPI AG, 2021-01-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Deferasirox (DFX) is an oral iron chelator used to reduce iron overload (IO) caused by frequent blood cell transfusions in anemic myelodysplastic syndrome (MDS) patients. To study the molecular mechanisms by which DFX improves outcome in MDS, we analyzed the global gene expression in untreated MDS p...